ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/02/20

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Japan’s Ministry of Health, Labour and Welfare has approved Alexion Pharmaceuticals' (ALXN) Ultomiris (ravulizumab) for atypical hemolytic uremic syndrome (aHUS), for use in adults and children.Ultomiris is a long-acting C5 inhibitor for aHUS and is administere...

– ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS, reducing the treatment burden for adults and children with administration every other month – – ULTOMIRIS has the potential to become the new standard of care in Japan for the treatment o...

The healthcare sector has been led by the biotech and pharmaceutical industries. These industries have led the fight against COVID and cancer. Here are four biotech stocks that should continue to benefit from current trends: Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Genmab A/S (GMAB) and,...

Moderna (MRNA) is one of the leading biotech manufacturers in the race to develop a coronavirus vaccine. The stock seems overvalued by traditional measures, but the company’s unique approach to developing the vaccine could move the stock in either direction.   Moderna, Inc. (...

Alexion Pharmaceuticals (ALXN) announces that the Committee for Medicinal Products for Human Use ((CHMP)) has adopted a positive opinion, recommending marketing authorization in the European Union for a new 100 mg/mL intravenous ((IV)) advanced formulation of ULTOMIRIS (ravulizumab).ULTOMIRIS...

– If approved, the new 100 mg/mL formulation will reduce infusion time by approximately 60%, lessening the burden on patients and health systems – – ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic...

This article series shows every month a dashboard with aggregate industry metrics in healthcare. Most of the companies used to calculate these metrics are holdings of the Health Care Select Sector SPDR ETF ( XLV ). Therefore, this is also a top-down survey of XLV. Shortcut If you are use...

Alexion Pharmaceuticals ( ALXN +6.5% ) is up on double normal in apparent response to rumors that Biogen ( BIIB +0.0% ) may be eyeing the company. More news on: Alexion Pharmaceuticals, Inc., Biogen Inc., Healthcare stocks news, Merger & acquisition news, Stocks on the move, Re...

Fortress Biotech (NASDAQ: FBIO ) announces that Caelum Biosciences in collaboration with Alexion Pharmaceuticals (NASDAQ: ALXN ) have initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101, an amyloid fibril targeted therapy, ...